Professory of Surgery
University of California, San Diego, California, United States
Dr. Jason Sicklick received his medical degree from the UCLA School of Medicine, completed his general surgery residency at The Johns Hopkins Hospital, and completed a fellowship in surgical oncology at Memorial Sloan Kettering Cancer Center. He joined the UC San Diego Division of Surgical Oncology at Moores Cancer Center in 2010. He is an NIH and FDA R01 funded investigator, Professor of Surgery and Adjunct Professor of Pharmacology, Executive Vice Chair of Research in the Department of Surgery, Associate Program Director of the General Surgery Residency, and Co-Leader of the Sarcoma Disease Team at the UC San Diego Moores Cancer Center. He is a board-certified general surgeon and surgical oncologist specializing in the treatment of complex retroperitoneal and abdominal sarcomas, including gastrointestinal stromal tumors (GIST), as well as hepatobiliary cancers. In 2016, Dr. Sicklick was named the GIST Clinician of the Year by the Life Raft GIST Support Group, the largest GIST patient advocacy group in the world. In 2018 he also received the RARE Champion of Hope in Medical Care & Treatment Award from the Global Genes-Allies in Rare Disease, the largest global non-profit advocacy organization for individuals and families fighting rare and genetic diseases. In 2021, he received the Rare Impact Award from the National Organization for Rare Disorders (NORD®). Dr. Sicklick is currently an active member of the National Comprehensive Cancer Network Soft Tissue Sarcoma Committee and GIST Subcommittee, and the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG), amongst several national/international committees. He also serves on the medical advisory boards of The Life Raft Group, and co-chairs Study Section Panel B (Translational) of the Israel Cancer Research Fund. His translational and clinical research focus on molecular mechanisms of GIST, as well as precision medicine approaches to cancer therapy for advanced cancers.
Disclosure information not submitted.
Wednesday, February 9, 2022
10:00 AM – 11:30 AM
Wednesday, February 9, 2022
11:00 AM – 11:30 AM